Nautilus Biotechnology (NasdaqGS:NAUT) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Company ParticipantsKen Suzuki - CMOAnna Mowry - CFOWilliam Ruby - Equity Research AssociateJi-Yon Yi - Investor Relations OfficerSujal Patel - CEOOperatorGood day, and thank you for standing by. Welcome to the Nautilus Biotechnology Third Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask ...

MIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report third quarter 2025 financial results and provide a business update on Tuesday, November 4, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Co ...

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics. Investors have until December 15, 2025, to ask the Court to be app ...

UNIONDALE, NY, Oct. 28, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and consumer products company, today announced that it has engaged RedChip Companies (“RedChip”) to lead its investor relations efforts. “We are entering a transformative phase for ProPhase,” said Ted Karkus, CEO and Chairman of ProPhase Labs. “With the imminent commercialization of our BE-Smart™ esophageal cancer diagnostic, continued expansion of our Nebul ...

Greenlight Capital, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Greenlight Capital funds returned -3.6% in the quarter, net of fees and expenses, compared to 8.1% for the S&P 500 index. The fund returned 0.4% in YTD compared to 14.8% for the index. For more information on the fund’s top picks in 2025, please check its top five holdings. In its third-quarter 2025 investor letter, Greenlight Capital highlighted stocks suc ...

公司资本结构优化 - 公司通过最大股东行权及部分权证到期 合计清理了约2000万份普通股认购权证 简化了资本结构并减少了潜在的股权稀释 [1][3] - 最大股东行使了905万份平价权证 行权价格为每股0.05加元 为公司带来45.25万加元的现金收益 增强了公司的现金状况 [2] - 另有11,116,667份权证于2025年10月26日到期未行权 进一步减少了权证悬置 [3] 财务状况增强 - 权证行权获得的45.25万加元现金将用于支持公司持续运营和战略性增长计划 增强了资产负债表 [2] - 公司通过发行714,286股普通股以每股0.07加元的认定价格 结算了约5万加元的未偿还债务 此举旨在保留现金用于营运资金 [4][5] - 结合近期的商业进展 这些举措标志着公司在增强财务灵活性和维持精简高效资本结构方面达到了新的里程碑 [6] 管理层观点与业务背景 - 公司首席执行官表示 最大股东的行权是对公司进展、战略和未来潜力的有力认可 这些发展巩固了公司本已强劲的资产负债表 [4] - 公司是一家专注于生产营养保健品和大麻素产品的加拿大生物技术公司 其拥有创新的植物基MyCell Technology®递送系统 旨在提高生物利用度和吸收效果 [8]

ANNOUNCEMENT NO. 295 28 October 2025 Upgrade of guidance ChemoMetec experiences an increased interest in its technology, not the least the XcytoMatic platform, and consequently expects a positive trend in revenue and profit particularly in the last part of the financial year 2025/26. Consequently, revenue in the financial year 2025/26 is now expected to be DKK 565-580 million against the most recently announced DKK 545-565 million, while EBITDA is expected to be in the range of DKK 320-335 million compared ...

Virtus LifeSci Biotech Clinical Trials ETF (BBC) is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and moved up 138.3% from its 52-week low price of $13.42/share.Are more gains in store for this ETF? Let us take a quick look at the fund and the near-term outlook on it to get a better idea of where it might be headed.BBC in FocusThe underlying LifeSci Biotechnology Clinical Trials Index is an equal weighted index that is designed to measure the equity market performanc ...

Several healthcare and biotech stocks posted notable gains in after-hours trading on Monday, driven by earnings updates, executive appointments, and capital market activity.Pulmonx Corp. (LUNG) surged 33.33% to $2.08 as of 9:36 PM EDT. The company announced preliminary, unaudited third-quarter 2025 revenue of about $21.5 million. Pulmonx also rescheduled its Q3 financial results release to Wednesday, November 12, 2025, after market close. In a leadership update, Glen French was reappointed as President and ...

By Christine Chen and Rishav Chatterjee SYDNEY (Reuters) -Australian biotech CSL has cut its profit outlook and delayed plans to spin off its vaccine division, blaming an unprecedented fall in U.S. flu immunisation rates, which knocked its shares down as much as 16.6% to a near seven-year low. At CSL’s annual meeting in Melbourne on Tuesday, investors frustrated with the former market darling's tanking share price also rejected executive pay packages for the second year in a row, but the board survived a ...